Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462754 | 0.79 | SCN9A (0.35) | PTGS2PTGS1SCN9AGRIA2 | |
| SCHEMBL1463227 | 0.78 | SCN9A (0.36) | PTGS2PTGS1SCN9AGRIA2 | |
| SCHEMBL1460060 | 0.77 | CYP2C9 (0.37) | PTGS2PTGS1SCN9A | |
| SCHEMBL1463766 | 0.77 | SCN9A (0.40) | PTGS2PTGS1SCN9A | |
| SCHEMBL1459990 | 0.75 | PTGS2 (0.39) | PTGS2PTGS1SCN9APDPK1 | |
| SCHEMBL27878706 | 0.74 | PTGS2 (0.34) | PTGS2PTGS1SCN9APDPK1 | |
| SCHEMBL18853892 | 0.74 | PTGS2 (0.46) | PTGS2PTGS1SCN9AGRIA2 | |
| SCHEMBL1463695 | 0.73 | SCN9A (0.40) | PTGS2PTGS1SCN9APDPK1 | |
| SCHEMBL12826525 | 0.72 | GRIA2 (0.36) | PTGS2PTGS1SCN9APDPK1GRIA2 | |
| SCHEMBL1459991 | 0.66 | SLC2A1 (0.37) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | claimed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | PTGS2 876/4885PTGS1 656/4885SCN9A 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.